The New U.S. Patent Law and other Recent Developments in Patents and Investor Perspective in Global IP Management
29 September 2011
- Heisse Kursawe Eversheds
80333 München, Germany
12:30 p.m. to 5:15 p.m.
(Starts with Lunchbuffet)
On September 8, 2011, the U.S. Congress passed the Leahy-Smith America Invents Act, H.R. 1249, which will be effective upon signature by President Obama. There are more changes made to the patent law and practice than at any time since the law of 1836 creating the Patent Office and an examination system. What provisions are effective immediately? Retroactively? How is "first to file" being implemented? This development, on top of a continuous stream of IP cases before the U.S. Supreme Court and the USPTO reexamination reform, is setting in motion the tidal wave of change in the IP landscape on both sides of the pond. It will likely have a profound effect on how IP assets are obtained, transacted, and enforced in the United States, Europe, and elsewhere in the world. European businesses with a global footprint must ensure their IP strategy is balanced and on target for competitive survival and long-term growth as these changes unfold.
IP and business attorneys from Foley, in collaboration with Eversheds LLP, invite you to join fellow IP leaders in Europe for a complimentary educational and interactive seminar on September 29, 2011.
- Leahy-Smith America Invents Act
How you can decipher transition provisions, grace period, and unclear issues, including first-to-file, overruling of Hilmer, "secret" prior art for obviousness, secret commercialization in any country, and other changes.
- Patent Paranoia, Beware!
Therasense and patent inequitable conduct, IDS burdens, Foreign Office Actions, and scaremongers: Cutting through the paranoia for simple, direct prosecution.
- How Emerging Technology Companies Manage Global IP Portfolios in the Face of Changing IP Laws
- U.S. Hot Topic Round-Up
Myriad (gene patenting); Mayo v. Prometheus (§ 101 patent-eligibility of personalized medicine); Classen v. Biogen IDEC; changes in interference/post-grant review; and alternative fee arrangements in U.S. patent litigations.
- European IP Update
Adrian Toutoungi, Partner, Intellectual Property & Technology Group
Rouget F. (Ric) Henschel, Partner, Chemical, Biotechnology & Pharmaceutical Practice, and Co-Chair, Life Sciences Industry Team
Stephen B. Maebius, Partner and Chair, IP Department
Sven Riethmueller, Partner, Private Equity & Venture Capital Practice
Kristel Schorr, Partner, Chemical, Biotechnology & Pharmaceutical Practice
Harold C. Wegner, Partner, IP Department
This seminar is offered free of charge for clients and key contacts of Foley and Eversheds. This program is reserved for corporate counsel and executives.
For specific information on the content of this seminar, please contact Mayumi Wille at email@example.com.
Foley & Lardner LLP will apply for U.S. CLE credit after the program, wherever applicable. Foley & Lardner LLP certifies that this activity has been approved for California MCLE credits by the State Bar of California in the amount of one General credit(s). Foley & Lardner LLP is a State Bar of California MCLE approved provider. Please note that participants must be in attendance on the date of the event; credit may not be obtained by viewing and/or listening to a program recording after the event.